Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation. Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48)
A szélütés és a halálozás kockázata a pitvarfibrilláció különböző típusaiban szenvedő betegekben. Az ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48) tanulmány eredményei.
Mark S. Link, Robert P. Giugliano, Christian T. Ruff, Benjamin M. Scirica, Heikke Huikuri, Ali Oto, et al. on behalf of the ENGAGE AF-TIMI 48 Investigators
Circulation: Arrhythmia and Electrophysiology. 2017;10(1):e004267,
DOI:https://doi.org/10.1161/CIRCEP.116.004267
